MSD Looks Ahead For Japan Growth Amid Policy Challenges
This article was originally published in PharmAsia News
Executive Summary
Despite a stream of new launches over the past few years, last year was a “challenging” one for MSD in Japan due mainly to generic competition, but the company expects the new products to help drive growth over the next few years.
You may also be interested in...
Firms, Japan Govt, Sued Over HPV Vaccines
A group of plaintiffs and their lawyers have now confirmed they will bring legal action in Japan later this month seeking damages against the country’s government and two multinational manufacturers of HPV vaccines over claims the products caused a variety of health problems.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.